HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2

PURPOSE: Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2+) breast cancers escape from these drug combinations. In this study, we sought to discover the mechanism...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Hanker, Ariella B., Garrett, Joan T., Estrada, Mónica Valeria, Moore, Preston D., Ericsson, Paula González, Koch, James P., Langley, Emma, Singh, Sharat, Kim, Phillip S., Frampton, Garrett M., Sanford, Eric, Owens, Philip, Becker, Jennifer, Groseclose, M. Reid, Castellino, Stephen, Joensuu, Heikki, Huober, Jens, Brase, Jan C., Majjaj, Samira, Brohée, Sylvain, Venet, David, Brown, David, Baselga, José, Piccart, Martine, Sotiriou, Christos, Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540793/
https://ncbi.nlm.nih.gov/pubmed/28381415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2287
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados